1º encontro TdC - Simpósio Anual de Atualização em Clínica Médica. 

Não é apenas mais um congresso. Queremos construir um encontro que faça sentido para a prática. Fruto de uma curadoria das atualizações mais relevantes, traduzidas em aulas dinâmicas focadas no que realmente importa para a sua tomada de decisão.

Garanta sua vaga através do link: https://www.tadeclinicagem.com.br/eventostdc/1-encontro-tdc/

🚨 www.tadeclinicagem.com.br/guia - Conheça o Guia TdC com 7 dias grátis 🚨

Pedro e Fred discutem sobre os principais efeitos colaterais dos anti-inflamatórios (renal, cardíaco e gastrintestinal) e sobre o uso tópico dos anti-inflamatórios.
Veja o vídeo do Resumo Visual de 8 minutos com os principais destaques do episódio de AINES: https://youtu.be/e7Yz6oG6KsM
 
Referências:

1. Derry, Sheena, et al. "Topical NSAIDs for chronic musculoskeletal pain in adults." Cochrane Database of Systematic Reviews 4 (2016).

2. Derry, Sheena, et al. "Topical NSAIDs for acute musculoskeletal pain in adults." Cochrane database of systematic reviews 6 (2015).

3. Baker, Megan, and Mark A. Perazella. "NSAIDs in CKD: are they safe?." American Journal of Kidney Diseases 76.4 (2020): 546-557.

4. Sharma, Leena. "Osteoarthritis of the knee." New England Journal of Medicine 384.1 (2021): 51-59.

5. Klinge, Stephen A., and Gregory A. Sawyer. "Effectiveness and safety of topical versus oral nonsteroidal anti-inflammatory drugs: a comprehensive review." The Physician and sportsmedicine 41.2 (2013): 64-74.

6. Drożdżal, Sylwester, et al. "Kidney damage from nonsteroidal anti‐inflammatory drugs—Myth or truth? Review of selected literature." Pharmacology Research & Perspectives 9.4 (2021): e00817.

7. Nissen, Steven E., et al. "Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis." New England Journal of Medicine 375 (2016): 2519-2529.
8. Laine, L., et al. "Risk factors for NSAID‐associated upper GI clinical events in a long‐term prospective study of 34 701 arthritis patients." Alimentary pharmacology & therapeutics 32.10 (2010): 1240-1248.
9. Masclee, Gwen MC, et al. "Risk of upper gastrointestinal bleeding from different drug combinations." Gastroenterology 147.4 (2014): 784-792.

10. Henry, David, et al. "Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis." Bmj 312.7046 (1996): 1563-1566.

11. Kelly, Judith P., et al. "Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product." The Lancet 348.9039 (1996): 1413-1416.

12. Rodríguez, Luis A. García, and Laura Barreales Tolosa. "Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population." Gastroenterology 132.2 (2007): 498-506.
13. Lanza, Frank L., et al. "Guidelines for prevention of NSAID-related ulcer complications." Official journal of the American College of Gastroenterology| ACG 104.3 (2009): 728-738.
14. Desai, Jay C., et al. "Primary prevention of adverse gastroduodenal effects from short-term use of non-steroidal anti-inflammatory drugs by omeprazole 20 mg in healthy subjects: a randomized, double-blind, placebo-controlled study." Digestive diseases and sciences 53.8 (2008): 2059-2065.

15. Takeuchi, Ken, et al. "Prevalence and mechanism of nonsteroidal anti-inflammatory drug–induced clinical relapse in patients with inflammatory bowel disease." Clinical Gastroenterology and Hepatology 4.2 (2006): 196-202.

16. Chey, William D., et al. "ACG clinical guideline: treatment of Helicobacter pylori infection." Official journal of the American College of Gastroenterology| ACG 112.2 (2017): 212-239.